AAV-vector based gene therapy for mitochondrial disease: progress and future perspectives.

Area of Science:

• Genetics
• Molecular Biology
• Neurology

Background:

• Mitochondrial diseases are rare genetic disorders impacting energy metabolism.
• These conditions cause severe multi-organ damage, particularly in high-energy tissues.
• Current treatments are limited, highlighting an urgent therapeutic need.

Purpose of the Study:

• To review preclinical findings of adeno-associated virus (AAV) vector-based gene replacement therapy.
• To assess the potential of AAV as a gene therapy vehicle for mitochondrial diseases.
• To summarize research on AAV gene therapy for specific conditions like Leigh syndrome and Barth syndrome.

Main Methods:

• Review of preclinical studies investigating AAV vector-based gene replacement.
• Analysis of AAV's characteristics as a gene delivery system for mitochondrial disorders.
• Summary of research findings for various mitochondrial diseases.

Main Results:

• Adeno-associated virus (AAV) demonstrates potential as a gene therapy vector due to its safety and ability to transduce quiescent cells.
• Preclinical studies show promise for AAV-based gene replacement in several mitochondrial diseases.
• AAV gene therapy is under investigation in clinical trials for Leber hereditary optic neuropathy.

Conclusions:

• AAV vector-based gene replacement is a promising therapeutic strategy for monogenic mitochondrial diseases.
• Further preclinical research supports the development of AAV gene therapy for conditions like Leigh syndrome, Barth syndrome, and ethylmalonic encephalopathy.
• Gene therapy holds potential to address the significant unmet medical needs in mitochondrial disease treatment.